HEAL Committee Report

1.

Health Canada make the necessary adjustments to the Special Access Program such that

a)

any costs that place an undue burden on a patient are absorbed by the federal government and,

b)

the bureaucratic burden is reduced;

2.

Health Canada report annually to the Standing Committee on Health through the House of Commons on the status of animal-sourced as well as human recombinant insulins;

3.

Health Canada request significant advance notice from Eli Lilly, (for example, five years), on any change in the company’s policy regarding the provision of animal-sourced insulins;

4.

Health Canada, in partnership with the Canadian Food Inspection Agency, facilitate the work done by Eli Lilly through active support for various measures, including the provision of tissue for insulin purification through the relationship established between the Agency and the abattoirs;

5.

Health Canada work closely with the Food and Drug Administration of the United States such that a concerted strategy is developed to ensure a North American supply of animal-sourced insulins; and

6.

Health Canada work closely with the Canadian Medical Association, the Royal College of Physicians and Surgeons of Canada and other professional bodies to ensure that the use of animal-sourced insulins is an option considered in the education and subsequent practice of physicians.